Two glycylcyclines have been tested against 191 strains of methicillin-resistant Staphylococcus aureus, 72 of which were resistant to minocycline, isolated from many parts of the world. MICs of CL 329998 ranged from 0.06 to 4 mg/L, with MIC, and MIG» 0.5 and 2 mg/L, respectively. CL 331002 was slightly less potent, having an MIC range 0.12-16 mg/L and MIC50 and MIG» values of 1 and 4 mg/L, respectively.
Introduction
The tetracyclines have been available for more than 40 years, during which time bacterial resistance has eroded their clinical usefulness (Speer, Shoemaker & Salyers, 1992) . Chemical manipulation at the 5, 6 and 7 positions resulted in two important derivatives, doxycycline and minocycline, with markedly improved pharmacokinetic and microbiological properties compared with the natural products. However, for the past 20 years there have, until now, been no significant advances in this field.
Recently, modifications of the D ring of tetracyclines in the 9 position have given rise to a series of compounds referred to as the glycylcyclines (Testa et al., 1993) . Two of these, the N-N-dimethylglycylamido derivatives of minocycline (CL 329998) and of 6-demethyl-6-deoxytetracycline (CL 331002), have excited considerable interest, as they are active in vitro against tetracycline-resistant strains harbouring efflux (tet A-tet D, and tet K) and ribosomal protection (tetM) genes (Testa et al., 1993; Eliopolous et al., 1994; Goldstein, Kitzis & Acar, 1994) . If they live up to the expectations raised by these in-vitro results, the glycylcyclines could rejuvenate the tetracyclines as a therapeutic class.
A pathogen that is causing considerable problems in terms of treatment options is methicillin-resistant Staphylococcus aureus (MRSA). MRSA is found world wide, and some isolates may be resistant to antibiotics from as many as 11 different chemical classes (Maple, Hamilton-Miller & Brumfitt, 1989) . While there is a perception that MRSA strains are almost always sensitive to minocycline (Freeman, Nightingale & Quintiliani, 1994) , this is based on results obtained with isolates from single locations, and in many reports on susceptibility patterns of MRSA neither tetracycline nor minocycline was tested. On the contrary, we (Maple et al., 1989) found a high incidence
•Tel: +44-(171)-794-0500; Fax: +44-{l71 (-435-9694. of resistance to minocycline (72% of strains having MIC ^ 16 mg/L) among 106 strains of MRSA collected from 21 countries. Although several groups have tested glycylcyclines against MRSA (Testa et al, 1993; Eliopolous et al., 1994; Goldstein et al., 1994; Weiss, Jacobus, Petersen & Testa, 1995) , many of the strains were sensitive to tetracycline and almost all were sensitive to minocycline, so the observation that they were sensitive to the glycylcyclines was entirely predictable. The question thus remains as to whether glycylcyclines are active against MRSA that are minocycline-resistant. To address this, we have tested two glycylcyclines against a large number of MRSA with varying patterns of susceptibility to tetracycline and minocycline, and have analysed our results separately for strains of differing resistance phenotypes.
Materials and methods

Microbiological methods
One hundred and ninety one strains of MRSA, from 26 countries, were tested. The plate dilution method, with IsoSensitest agar (Unipath, Basingstoke, UK) and an inoculum of 10*cfu per spot, was used to determine MICs of tetracycline, minocycline and two glycylcyclines, CL 329998 and CL 331002 (Lederle Laboratories, Hants, UK).
Analysis of data
For the purposes of analysis the strains were divided into four phenotypic groups, according to their susceptibility to tetracycline and minocycline: group A, tetracycline-sensitive, minocycline-sensitive (34 strains); group B, tetracycline-resistant, minocycline-sensitive (42 strains); group C, tetracycline-resistant, minocycline-intermediate (43 strains); and group D, tetracycline-resistant, minocycline-resistant (72 strains).
MIC findings were summarized in terms of the MICjo, MIGw, I50, I90 (calculated by cumulation and interpolation), and geometric mean MICs.
Breakpoints
There do not appear to be any definitive breakpoints for minocycline when (as recommended by the Working Party of the BSAC, 1991) IsoSensitest agar is used. We therefore took as working values those recommended by The National Committee for Clinical Laboratory Standards (NCCLS, 1993) and the Comite de l'Antibiogramme de la Societe Francaise de Microbiologie (Soussy et al., 1994) . Thus, sensitive, intermediate and resistant strains were defined as having MICs <,4, 8 and > 16 mg/L, respectively. The same breakpoints were taken for tetracycline, as recommended when using IsoSensitest agar (Oxoid, 1980) .
Results and discussion
The results ( Table) make it clear that both glycylcyclines are active against minocycline-resistant MRSA. Combining findings for all 191 MRSA strains, CL 329998 was slightly more active than CL 331002 (geometric mean MIC 0.75 mg/L compared with 1.14 mg/L, respectively). Strains in group B, being sensitive to minocycline but resistant to tetracycline, will probably be of genotype let K, while those in group D (resistant to both tetracycline and minocycline) are likely to be of genotype let M (Speer et al., 1992) . Group C strains, although of "intermediate" susceptibility to minocycline, were only slightly more resistant to tetracycline and the glycylcyclines compared with strains in group B. However, group D strains were approximately 3-fold less susceptible to all four compounds than those in group C. Unlike the situation with coagulase-negative staphylococci, as described by Archer & Climo (1994) , both glycylcyclines were more active than minocycline against MRSA of assumed genotype let K.
There was a clear geographical difference in the incidence of minocycline resistance among the MRSA tested. For example, while 62% (18/29) of strains from the Americas were sensitive (MIC <, 4 mg/L), only 27% (31/115) of European and Asiatic strains were susceptible (P < 0.001). It is important to bear in mind the possibility of such differences when assessing the potential value of new antibiotics against MRSA.
On the basis of our findings, CL 329998, the glycylcycline derived from minocycline, can be expected to be active in vitro against all MRSA; the only other freely available antibiotic class for which such a claim can be made is the glycopeptides.
